Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has provided an update.
On June 9, 2025, Microbot Medical announced the expansion of its commercial team with the addition of Michael Lytle as head of Sales Operations & Analytics, in preparation for the anticipated U.S. launch of the LIBERTY System in the third quarter of 2025. The company is actively engaged with the FDA, with a 510(k) decision expected in the same quarter, and this timeline is not expected to impact the planned launch, indicating confidence in their strategic growth and market readiness.
The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems.
Average Trading Volume: 2,468,032
Technical Sentiment Signal: Buy
Current Market Cap: $102.2M
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.